Mackay Shields LLC boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 18.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 59,839 shares of the biopharmaceutical company’s stock after buying an additional 9,183 shares during the quarter. Mackay Shields LLC’s holdings in Alexion Pharmaceuticals were worth $5,860,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in ALXN. Steward Partners Investment Advisory LLC bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $28,000. Redhawk Wealth Advisors Inc. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $29,000. Investors Research Corp raised its holdings in Alexion Pharmaceuticals by 52.0% during the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 104 shares during the last quarter. Ossiam bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $32,000. Finally, Capital Bank & Trust Co raised its holdings in Alexion Pharmaceuticals by 355.9% during the 2nd quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 210 shares during the last quarter. 94.68% of the stock is owned by hedge funds and other institutional investors.
Several analysts have weighed in on the company. Stifel Nicolaus reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. Cowen reissued a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, October 16th. Oppenheimer lowered their price target on Alexion Pharmaceuticals from $165.00 to $150.00 in a research note on Thursday, October 24th. Finally, BMO Capital Markets initiated coverage on Alexion Pharmaceuticals in a research note on Thursday, September 12th. They issued an “outperform” rating and a $149.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $159.00.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. Sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.41 earnings per share for the current year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: The role of implied volatility with call option volume
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.